Top 13 Microbiome startups in USA
Nov 18, 2025
|
Like
22
1
Funding: $1.6B
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
Ginkgo Bioworks is the organism company. We design custom microbes for customers across multiple markets. We build our foundries to scale the process of organism engineering using software and hardware automation. Organism engineers at Ginkgo learn from nature to develop new organisms that replace technology with biology.
2
Funding: $537.8M
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
Seres Therapeutics is creating a new class of medicines to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis
3
Funding: $437M
Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.
Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.
4
Funding: $397M
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
Evelo is pioneering therapies that modulate systemic immune response by acting on the gut-body network - monoclonal microbials. They have the potential to treat many diseases, including inflammatory disease, cancer, autoimmune disease, metabolic, neurobehavior and neuroinflammatory diseases.
5
Funding: $301M
Viome has developed technology aimed at balancing microorganisms in the gut. With Viome, you can fine-tune the function of your gut microbiome with a personalized diet to minimize the production of harmful metabolites and maximize the production of beneficial ones, so that you experience increased energy and general well-being, all while reaching and maintaining a healthy state of balance.
Viome has developed technology aimed at balancing microorganisms in the gut. With Viome, you can fine-tune the function of your gut microbiome with a personalized diet to minimize the production of harmful metabolites and maximize the production of beneficial ones, so that you experience increased energy and general well-being, all while reaching and maintaining a healthy state of balance.
6
Funding: $188.8M
Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing and delivering innovative therapies that harness the human gut microbiome.
Finch Therapeutics Group is a clinical-stage biopharmaceutical company focused on developing and delivering innovative therapies that harness the human gut microbiome.
7
Funding: $130.9M
Vertero Therapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
Vertero Therapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
8
Funding: $118M
Zoe is leading the world’s largest ongoing nutritional research project in collaboration with scientists from universities including Harvard, King's College London, Massachusetts General Hospital, Oxford and Stanford.
Zoe is leading the world’s largest ongoing nutritional research project in collaboration with scientists from universities including Harvard, King's College London, Massachusetts General Hospital, Oxford and Stanford.
9
Funding: $75.3M
Azitra is a preclinical-stage development company using a microbiome based platform to deliver innovative, inexpensive, and sustainable treatments for skin disease.
Azitra is a preclinical-stage development company using a microbiome based platform to deliver innovative, inexpensive, and sustainable treatments for skin disease.
10
Funding: $38,7m
AOBiome LLC is developing a transformative, new class of products based on Ammonia Oxidizing Bacteria (AOB) to improve skin health and prevent or treat skin and inflammatory diseases. The company’s probiotics are designed to provide cosmetic and therapeutic benefits by restoring the natural, protective balance afforded by beneficial skin microbes that have been lost due to modern living practices, including antibiotic use, soaps, and shampoos.
AOBiome LLC is developing a transformative, new class of products based on Ammonia Oxidizing Bacteria (AOB) to improve skin health and prevent or treat skin and inflammatory diseases. The company’s probiotics are designed to provide cosmetic and therapeutic benefits by restoring the natural, protective balance afforded by beneficial skin microbes that have been lost due to modern living practices, including antibiotic use, soaps, and shampoos.
11
Funding: $31M
Scioto Biosciences is committed to moving the field of microbiome therapeutics forward. By enabling beneficial bacteria colonization in the gut, we believe our novel Activated Bacterial Therapeutic (ABT) delivery platform technology will revolutionize therapeutic interventions for diseases where there is erosion of the mucosal barrier.
Scioto Biosciences is committed to moving the field of microbiome therapeutics forward. By enabling beneficial bacteria colonization in the gut, we believe our novel Activated Bacterial Therapeutic (ABT) delivery platform technology will revolutionize therapeutic interventions for diseases where there is erosion of the mucosal barrier.
12
Funding: $16.4M
Astarte Medical delivers technology platforms to address critical needs and improve outcomes for high risk pregnancy and preterm birth.
Astarte Medical delivers technology platforms to address critical needs and improve outcomes for high risk pregnancy and preterm birth.
13
Funding: $8.4M
Ombre is a provider of a microbiome testing kit designed to incorporate personalized probiotics and microbiome testing.
Ombre is a provider of a microbiome testing kit designed to incorporate personalized probiotics and microbiome testing.
★
See also:
